LITS
Lite Strategy, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.14
+9.62%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +62.4%
- EBIT
- +43.8%
- EPS
- -92.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -47.3%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +58.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026